The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma-Reference-Cited by-同舟云学术

The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma

Published:2013-04-05 Issue:2 Volume:2 Page:84-100
ISSN:2162-4933
Container-title:Current Dermatology Reports
language:en
Short-container-title:Curr Derm Rep

Author:

Pappas-Taffer Lisa,Rosenbach Misha,Chu Emily Y.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s13671-013-0039-9.pdf

Reference60 articles.

1. Manousaridis I et al. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol. 2013;27(1):11–8.

2. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist. 2009;14(8):848–61.

3. Davies H et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.

4. Platz A et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008;1(4):395–405.

5. Chapman PB et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatologic Toxicities of Anticancer Therapy;Abeloff's Clinical Oncology;2020

2. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview;Current Drug Safety;2019-01-17

3. Dermatologic Toxicities of Anticancer Therapy;Abeloff's Clinical Oncology;2014

4. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy;Melanoma Research;2013-12

5. Cutaneous Adverse Events to Type I BRAF Inhibitors: An Analysis of Effects Associated with Each Inhibitor and Therapeutic Time Interval to Onset;American Journal of Clinical Dermatology;2013-09-19